A new synthetic lethal strategy expands the application of PARP inhibitors/cisplatin

A new synthetic lethal strategy expands the application of PARP inhibitors/cisplatin

Bibliographic Details
Main Authors:	Jinrui Wang, Daniel D. Billadeau, Ying Zheng, Da Jia
Format:	Article
Language:	English
Published:	Wiley 2023-06-01
Series:	MedComm – Oncology
Online Access:	https://doi.org/10.1002/mog2.28

Similar Items

Filling in the gaps in PARP inhibitor-induced synthetic lethality
by: Mariana Paes Dias, et al.
Published: (2021-11-01)

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
by: Stephane Angers
Published: (2021-03-01)

Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia
by: John P. Brabson, et al.
Published: (2023-01-01)

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
by: Marina Kolesnichenko, et al.
Published: (2024-07-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
by: Zatreanu, D, et al.
Published: (2021)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
by: Diana Zatreanu, et al.
Published: (2021-06-01)

Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality
by: Gogola, E, et al.
Published: (2018)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
by: Margherita Turinetto, et al.
Published: (2021-06-01)

Synthetic lethality of cohesins with PARPs and replication fork mediators.
by: Jessica L McLellan, et al.
Published: (2012-01-01)

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
by: Thomas Helleday
Published: (2011-08-01)

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
by: Shuangying Li, et al.
Published: (2022-10-01)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.
by: Asim, M, et al.
Published: (2017)

Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells
by: Ilirjana Bajrami, et al.
Published: (2012-08-01)

Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
by: Liwei An, et al.
Published: (2022-05-01)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
by: Mohammad Asim, et al.
Published: (2017-08-01)

Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
by: Miaoqin Chen, et al.
Published: (2022-03-01)

Investigation into the relationship between PARPs in DNA repair and synthetic lethality with homologous recombination deficiency
by: Ronson, G
Published: (2017)

TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks
by: Jian Ma, et al.
Published: (2023-03-01)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
by: Juan Miguel Baquero, et al.
Published: (2022-05-01)

Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer
by: Celia D. Rouault, et al.
Published: (2025-03-01)

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
by: Hubert Fleury, et al.
Published: (2019-06-01)

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality
by: Paola Sanese, et al.
Published: (2020-10-01)

PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation
by: Asli Muvaffak, et al.
Published: (2024-05-01)

Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer
by: Shiue-Wei Lai, et al.
Published: (2020-04-01)

Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
by: Somaira Nowsheen, et al.
Published: (2012-01-01)

Update on Combination Strategies of PARP Inhibitors
by: Zhuoqun Lin, et al.
Published: (2024-11-01)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
by: Siddhant Bhoir, et al.
Published: (2023-11-01)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
by: Katherine Sullivan-Reed, et al.
Published: (2018-06-01)

Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
by: Hubert Fleury, et al.
Published: (2024-05-01)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
by: Mariya Yordanova, et al.
Published: (2021-12-01)

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
by: Sayani Bhattacharjee, et al.
Published: (2022-03-01)

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality
by: Vasily A. Yakovlev, et al.
Published: (2023-02-01)

Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.
by: Jones, D, et al.
Published: (2012)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
by: Victor M. Matias-Barrios, et al.
Published: (2023-01-01)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
by: Xiaoyu Fu, et al.
Published: (2024-01-01)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
by: Young-Hwa Soung, et al.
Published: (2023-10-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

Epigenetic based synthetic lethal strategies in human cancers
by: Aiai Gao, et al.
Published: (2020-09-01)

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
by: Daniela Criscuolo, et al.
Published: (2019-02-01)

Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer
by: Mensah, Lawrence B, et al.
Published: (2021)